About Amprion Inc
Amprion Inc is a Limited Liability Partnership company in United Kingdom. Its corporate identification number is (CIN) 261195143 and its current status is Active.
Key Metrics
CIN
261195143
Current Status
Active
Entity Type
Limited Liability Partnership
Latest Employee Count
17 as on Dec 31, 2022
Brands associated with Amprion Inc
There is one brand associated with Amprion Inc which include Amprion .
Name | Short Description | Founded Year | Location | Current Stage |
|---|---|---|---|---|
Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology | 2006 | Series B |
Financials of Amprion Inc
Funding and Investors of Amprion Inc
Amprion, the brand associated with Amprion Inc, has raised a total funding of $11.8M over 9 rounds. Its first funding round was on May 16, 2012. Its latest funding round was a Series B round on Jul 08, 2026 for $*****. 1 investor participated in its latest round. Amprion has 5 institutional investors.
Here is the list of recent funding rounds of Amprion:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 08, 2026 | 1706168 | Series B | 6239006 | 8427528 | 2398713 | 1805954 |
Oct 10, 2024 | 6568580 | Series B | 9473876 | 7413308 | 5750838 | |
Sep 12, 2024 | 3951829 | Grant (prize money) | 2385512 | 2575929 | 2218902 |
Competitors & Alternates of Amprion Inc
Amprion is the only brand associated with Amprion Inc, and here are its Top 10 competitors ranked by Tracxn score:
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Octave Bioscience 2014, Menlo Park (United States), Series C | Provider of AI-based molecular diagnostic tools for neurodegenrative diseases | $124M | 65/100 | |
2nd | Amprion 2006, Houston (United States), Series B | Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology | $11.8M | 56/100 | |
3rd | PeopleBio R&D 2002, Seongnam-si (South Korea), Public | Immunoassays for early detection of neuro-degenerative diseases | - | 48/100 | |
4th | Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases | - | 40/100 | ||
5th | Cytox 2007, Oxford (United Kingdom), Series B | Developer for prognostic tests for assessing the risk of dementia | $12.1M | 38/100 | |
6th |  LikeMinds 2008, Boston (United States), Series A | Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases | $6.37M | - | 35/100 |
7th |  Durin Life Sciences 2010, United States, Acquired | Early disease detection blood tests for Alzheimer's and Parkinson's | $5.5M | - | 34/100 |
8th | Alseres Pharmaceuticals 1972, Auburndale (United States), Public | Therapeutic and diagnostic products for disorders in the central nervous system (CNS) | $4M | 34/100 | |
9th |  Durin Technologies 2010, Camden (United States), Series B | Developer of the diagnostic test for neurodegenerative diseases | $8.05M | 32/100 | |
10th | Gene Solutions 2006, Charlottesville (United States), Series A | Pioneering mitochondrial medicine, developing therapeutics for neurodegenerative and muscular diseases | $6.33M | - | 32/100 |
News related to Amprion Inc
Media has covered brands linked with Amprion Inc for a total of 3 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
Amprion Partners with MLM Medical Labs to Expand Alpha-Synuclein SAA Testing in EuropeBusiness Wire•Aug 12, 2026•Amprion, MLM
•
•
Amprion and Energinet advance offshore interconnector between Germany and DenmarkWindtech-International•Jan 27, 2026•Energinet, Amprion
•
•
•
RWE partners with Apollo for Amprion stake fundingWindtech-International•Sep 08, 2025•RWE, Apollo Global Management, Amprion
•
•
•
•
ALS Network Announces $100,000 Research Grant Awarded to Amprion, Inc.PR Newswire•Sep 12, 2024•Amprion, ALS Network
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Attribution:
Contains public sector information licensed under the Open Government License v3.0.
FAQs about Amprion Inc
Explore our recently published Legal Entities
